Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 0.00 0.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8676 to 8698 of 8900 messages
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
DateSubjectAuthorDiscuss
18/5/2020
12:48
Welcome, Bigwig!
bones
18/5/2020
10:58
In fact it's the equivalent of a hidden IED!
langland
18/5/2020
10:49
Good man, Bigwig. There definitely seems to be a bit more interest this AM. I wonder if a few more people are catching up with....'The valve design and manufacturing method are both major improvements and the Board believes that the combination has produced one of the largest step changes in heart valve technology over the last 20 years.' which seems to have been lost in the middle of last week's trading update.
langland
18/5/2020
10:45
Mind if I join in, I agree about the spread not being as wide as shown as I also bought this morning, fresh from success with BATM, this one looks interesting with a small market cap and that also puts off some investors but for me it makes it more attractive. I found the comments in this thread very helpful too. Will look to buy more in stages if they start moving up.
bigwig
18/5/2020
09:47
Real spread is tighter because I bought more this AM but agree the spread as advertised would be a put off.
langland
18/5/2020
08:41
I think the spread is a put-off, but that is the nature of the share.
semper vigilans
18/5/2020
08:37
GR, it seems inevitable it will happen eventually. The developments are too compelling. Unfortunately right now the spare money in the market is heading to all the Covid stocks, some justified, some not. I saw a tweet at the weekend by one excitable fellow who said something on the lines of “I thought this was a bubble but now I’ve seen the light”. That’s a bubble style comment if ever I saw one! As for AOR, someone saw the light this morning and spent £300......
bones
18/5/2020
08:32
This co is in the thick of disruptive medical technology - shame the market doesn't recognise and run with that theme. Just needs to get noticed by a few new buyers and we'll breakout IMO.
greedy rooster
17/5/2020
13:40
Bumping this up as someone disturbed the dead thread!
bones
15/5/2020
14:26
SV, nail on head. Nonetheless, I’d be amazed if the entire board of directors are not tapping up everyone they know in the industry with this development. John Ely must be salivating about it over there in the States!
bones
15/5/2020
11:13
Nobody recognises good news Bones but they revel in bad news!
semper vigilans
15/5/2020
10:30
I second this: https://twitter.com/foursidedfiver/status/1261225365537685504?s=21 Hands up, I also wrote it! I think it is time that the achievements being made by this company got some kind of wider audience. My efforts won’t get much done but maybe the right people on Twitter can spread the word. Seems to work for the virus hunters promoting their stocks across the twitter sphere!
bones
14/5/2020
12:11
Agree with that, GR. I recall hearing from the company that they regard the value inherent in any IP related to this novel manufacturing process to be significant and a crucial part of the overall proposition. It is therefore good to know they have their IP professionals on the case.
bones
14/5/2020
11:53
The update yesterday was excellent. The value added in terms of IP should not be overlooked. The whole process has required patience but they are approaching the projects in exactly the right way, ultimately smoothing the difficult path to regulatory approval. The share price suggests limited chance of success - the non-exec share options were entrepreneurial and align our interests. I think this looks really good.
greedy rooster
14/5/2020
10:54
The much cheaper unit cost potentially of producing polymer valves compared to current tissue based ones will be one catalyst? If the breakthrough that I understand the new novel processing equipment represents achieves such a unit cost production, then that would start to fracture the walls of resistance. The concomitant ability to offer competitive pricing in an atmosphere of resistance to high medical costs, especially in the US, could be another. Societal resistance to exploiting animal flesh could be yet another?
bones
14/5/2020
10:25
Langland The regulators allow animal tissue if there is no real alternative. Once an alternative is approved, the regulators will push the medtech companies to use alternative material too. Remember the sunk cost and investment in the current devices out there and the great margins they achieve. The medtechs need a catalyst to start canabalising that margin.
landy90
14/5/2020
09:42
I would not disagree with north of 200p. AS a former shareholder in AGL I occasionally make comparison with AOR/RUA. I regard yesterday's HV update as similar to AGL's announcement in 2011 when they first captured ctcs with Parsortix. The mkt. cap. went from about £12mn to £35mn within a few weeks. And AGL's underlying business was nowhere near as strong as AOR's. The FDA has already allowed the implantation of polymeric valves in humans and elasteon has been proved over many years. AGL is still waiting for FDA approval 11 years later and its mkt. cap is £110mn after the seemingly endless issue of shares. The other and very significant point is simply about the use of polymer instead of all the animal tissue which is used in these medical devices. My wife has a bit of pig in her after a breast reconstruction-ghastly thought. You would think that after this virus outbreak that the medtech companies would have had enough of animal tissue.
langland
14/5/2020
09:11
We're not actually that far from new highs under the new business plan era. And as we know this can move very strongly with the right news. I still believe we'll exit 2020 well over 200p.
someuwin
14/5/2020
08:47
It’s easier for them to pick on companies with problems apart from the odd one who ‘might’ have a vaccine for CoVID19.
semper vigilans
14/5/2020
08:41
“The valve design and manufacturing method are both major improvements and the Board believes that the combination has produced one of the largest step changes in heart valve technology over the LAST 20 YEARS.” It would be nice to think that David, Bill and the entire board are out there right now pummelling this observation into the heads of the worldwide industry! Could do with some of the newspapers and media outlets picking it up too. What do the Health and City Desk editors do with their time these days? There are no pubs to go to at lunchtime so get some research done, boys and girls, and publish a rare good news story for once!
bones
13/5/2020
14:05
I’ve raised the name mistake and the heart valve risk adjustment query with Equity Development by way of a reply to their twitter feed. You have got to get it right if you are going to use twitter to trumpet your client’s achievements. It reflects badly on everyone to be less than professional.
bones
13/5/2020
13:54
Second unimpressed of ADVFN!
langland
13/5/2020
13:33
Strikes me as a bit of a lazy update by Equity Development, done in a rush I think, with messy grammar; not proof read I guess. Poor schoolboy error in the first paragraph, suggesting that the new name will be RUA Medical PLC when it has been flagged by the company as being RUA Life Sciences PLC. Very surprised they have made no change to their risk setting for heart valve exit value. This was a critical early stage to prove the feasibility of this tooling design. How does that not justify even a small adjustment to the risk factor? Unimpressed of ADVFN!
bones
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200712 23:51:27